CDC official overseeing COVID hospitalization data resigns
Digest more
Top News
Overview
Impacts
Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's respiratory syncytial virus vaccine in a broader age group. The mRNA-based RSV shot,
Covid-19 and RSV head data scientist dramatically quits saying she doesn’t trust RFK Jr department to use it ‘objectively’ - Fiona Havers had worked for the Centers of Disease Control for 13 years bef
Kennedy last week announced he would "retire" the entire panel that guides U.S. vaccine policy. He also quietly removed Dr. Melinda Wharton — the veteran Centers for Disease Control and Prevention official who coordinated the committee's meetings.
Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the company's respiratory syncytial virus vaccine in a broader age group.
The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the disease.
Explore more
10h
Zacks Investment Research on MSNEMA Accepts GSK's Filing for Expanded Use of RSV Vaccine ArexvyGSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to expand the use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine,
The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a lower group of adults aged 18 to 59 years at increased risk for disease. Moderna's RSV shot,
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.